Omalizumab in patients with severe asthma and persistent sputum eosinophilia

Omalizumab in patients with severe asthma and persistent sputum eosinophilia

Abstract Omalizumab, a recombinant humanized monoclonal antibody targeting the IgE molecule, is the first biologic approved for moderate-to-severe allergic asthmatics, who remain uncontrolled despite high dose inhaled corticosteroid and bronchodilators. Steroid-sparing effect of omalizumab has not b...

Full description

Bibliographic Details
Main Authors: Manali Mukherjee, Melanie Kjarsgaard, Katherine Radford, Chynna Huang, Richard Leigh, Delbert R. Dorscheid, Catherine Lemiere, Louis-Philippe Boulet, Susan Waserman, James Martin, Parameswaran Nair
Format: Article
Language:English
Published: BMC 2019-04-01
Series:Allergy, Asthma & Clinical Immunology
Subjects:
Severe asthma
Sputum eosinophils
Omalizumab
IgE
TSLP
Online Access:http://link.springer.com/article/10.1186/s13223-019-0337-2

Internet

http://link.springer.com/article/10.1186/s13223-019-0337-2

Similar Items